| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
|
Sci Transl Med
|
2011
|
3.46
|
|
2
|
The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice.
|
Psychopharmacology (Berl)
|
2003
|
1.83
|
|
3
|
Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688.
|
J Nucl Med
|
2007
|
1.48
|
|
4
|
Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats.
|
Psychopharmacology (Berl)
|
2001
|
1.47
|
|
5
|
Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats.
|
Psychopharmacology (Berl)
|
2004
|
1.47
|
|
6
|
Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5.
|
J Nucl Med
|
2006
|
1.32
|
|
7
|
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats.
|
J Pharmacol Exp Ther
|
2003
|
1.20
|
|
8
|
Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods.
|
J Nucl Med
|
2007
|
1.14
|
|
9
|
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
|
Mov Disord
|
2011
|
1.10
|
|
10
|
AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome.
|
Neurobiol Dis
|
2011
|
1.09
|
|
11
|
The challenges of clinical trials in fragile X syndrome.
|
Psychopharmacology (Berl)
|
2013
|
1.05
|
|
12
|
Metabotropic glutamate receptor mGluR5 is not involved in the early hemodynamic response.
|
J Cereb Blood Flow Metab
|
2011
|
1.01
|
|
13
|
Spiro[2.2]pentane as a dissymmetric scaffold for conformationally constrained analogues of glutamic acid: focus on racemic 1-aminospiro[2.2]pentyl-1,4-dicarboxylic acids.
|
J Org Chem
|
2002
|
1.01
|
|
14
|
Translating molecular advances in fragile X syndrome into therapy: a review.
|
J Clin Psychiatry
|
2014
|
1.00
|
|
15
|
Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
|
J Neurosci
|
2002
|
0.99
|
|
16
|
Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant.
|
Psychopharmacology (Berl)
|
2012
|
0.98
|
|
17
|
Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development.
|
Psychopharmacology (Berl)
|
2014
|
0.95
|
|
18
|
Metabotropic glutamate receptors: their therapeutic potential in anxiety.
|
Curr Top Behav Neurosci
|
2010
|
0.95
|
|
19
|
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion.
|
Drug Discov Today
|
2003
|
0.94
|
|
20
|
Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice.
|
Behav Brain Res
|
2012
|
0.93
|
|
21
|
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
|
Neuropharmacology
|
2010
|
0.92
|
|
22
|
Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers.
|
Eur J Nucl Med Mol Imaging
|
2007
|
0.91
|
|
23
|
mGlu5 receptor antagonists: a novel class of anxiolytics?
|
Drug News Perspect
|
2004
|
0.91
|
|
24
|
Quantitative evaluation of 11C-ABP688 as PET ligand for the measurement of the metabotropic glutamate receptor subtype 5 using autoradiographic studies and a beta-scintillator.
|
Neuroimage
|
2007
|
0.90
|
|
25
|
ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies.
|
Bioorg Med Chem
|
2006
|
0.89
|
|
26
|
Pharmacological modulation of mGluR7 with AMN082 and MMPIP exerts specific influences on alcohol consumption and preference in rats.
|
Addict Biol
|
2011
|
0.87
|
|
27
|
Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608).
|
Eur J Pharmacol
|
2002
|
0.86
|
|
28
|
Blockade of the mGlu5 receptor decreases basal and stress-induced cortical norepinephrine in rodents.
|
Psychopharmacology (Berl)
|
2005
|
0.85
|
|
29
|
The mGlu5 receptor antagonist MPEP activates specific stress-related brain regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: significance for the use as anxiolytic/antidepressant drug.
|
Neuropharmacology
|
2012
|
0.85
|
|
30
|
Neuroprotective activity of metabotropic glutamate receptor ligands.
|
Adv Exp Med Biol
|
2002
|
0.84
|
|
31
|
Development of mavoglurant and its potential for the treatment of fragile X syndrome.
|
Expert Opin Investig Drugs
|
2013
|
0.83
|
|
32
|
Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.
|
Neurobiol Aging
|
2009
|
0.82
|
|
33
|
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
|
Neuropharmacology
|
2013
|
0.82
|
|
34
|
Effects of metabotropic glutamate receptor 5 on latent inhibition in conditioned taste aversion.
|
Behav Brain Res
|
2005
|
0.81
|
|
35
|
Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
|
J Neurochem
|
2010
|
0.81
|
|
36
|
A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.
|
Mov Disord
|
2015
|
0.80
|
|
37
|
In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling.
|
Neuropsychopharmacology
|
2004
|
0.80
|
|
38
|
MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
|
Neuropharmacology
|
2012
|
0.79
|
|
39
|
Design and synthesis of selective and potent orally active S1P5 agonists.
|
ChemMedChem
|
2010
|
0.78
|
|
40
|
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
|
Parkinsonism Relat Disord
|
2011
|
0.78
|
|
41
|
The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro.
|
BMC Med Genet
|
2012
|
0.77
|
|
42
|
Synthesis and preliminary pharmacological evaluation of the four stereoisomers of (2S)-2-(2'-phosphono-3'-phenylcyclopropyl)glycine, the first class of 3'-substituted trans C1'-2'-2-(2'-phosphonocyclopropyl)glycines.
|
Bioorg Med Chem
|
2007
|
0.76
|
|
43
|
Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brain.
|
Brain Struct Funct
|
2014
|
0.75
|
|
44
|
Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [(11) C]ABP688 PET imaging.
|
Synapse
|
2014
|
0.75
|